485 related articles for article (PubMed ID: 25526639)
1. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
2. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
3. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation.
Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E
Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353
[TBL] [Abstract][Full Text] [Related]
4. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E; Ohnuma K; Yamazaki H; Hatano R; Iwata S; Okamoto T; Dang NH; Yamada T; Morimoto C
Biochem Biophys Res Commun; 2014 May; 447(4):609-15. PubMed ID: 24747072
[TBL] [Abstract][Full Text] [Related]
5. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
6. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.
Ohnuma K; Saito T; Hatano R; Hosono O; Iwata S; Dang NH; Ninomiya H; Morimoto C
J Clin Lab Anal; 2015 Mar; 29(2):106-11. PubMed ID: 24687574
[TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
[TBL] [Abstract][Full Text] [Related]
9. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
14. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
15. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
17. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
[TBL] [Abstract][Full Text] [Related]
18. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
19. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
[TBL] [Abstract][Full Text] [Related]
20. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
